Radiation-guided gene therapy of cancer

Technology in Cancer Research and Treatment

Volumn 5, Issue 4, 2006, Pages 437-443

  Han, Zhaozhong ^a   Wang, Hailun ^a   Hallahan, Dennis E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Radiation; Tumor endothelium

Indexed keywords

ADENOVIRUS VECTOR; BIOLOGICAL MARKER; CYSTEINE RICH PROTEIN 61; DNA; EARLY GROWTH RESPONSE FACTOR 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; PEPTIDE LIBRARY; PERLECAN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BIOINFORMATICS; BRAIN CANCER; CANCER THERAPY; CLINICAL TRIAL; CYTOTOXICITY; DNA MICROARRAY; ENDOTHELIUM; GENE AMPLIFICATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; HUMAN; LUNG CANCER; NONHUMAN; PHAGE DISPLAY; PROMOTER REGION; PROTEOMICS; RADIATION; RADIATION GUIDED GENE THERAPY; REVIEW; TUMOR XENOGRAFT;

EID: 33748079485     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460600500412     Document Type: Review

References (93)

1. Rosenberg, S. A. et al. Gene Transfer into Humans - Immunotherapy of Patients with Advanced Melanoma, Using Tumor-infiltrating Lymphocytes Modified by Retroviral Gene Transduction. N. Engl. J. Med. 323, 570-578 (1990).
2. Gottesman, M. M. Cancer Gene Therapy: An Awkward Adolescence. Cancer Gene Ther. 10, 501-508 (2003).
3. Glover, D. J., Lipps, H. J., and Jans, D. A. Towards Safe, Non-viral Therapeutic Gene Expression in Humans. Nat. Rev. Genet. 6, 299-310 (2005).
4. Hallahan, D. E., Spriggs, D. R., Beckett, M. A., Kufe, D. W., and Weichselbaum, R. R. Increased Tumor Necrosis Factor Alpha mRNA After Cellular Exposure to Ionizing Radiation. Proc. Natl. Acad. Sci. USA 86, 10104-10107 (1989).
5. Senzer, N. et al. TNFerade Biologic, An Adenovector With a Radiation-inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients with Solid Tumors. J. Clin. Oncol. 22, 592-601 (2004).
6. Joiner, M. C., Marples, B., Lambin, P., Short, S. C., and Turesson, I. Low-dose Hypersensitivity: Current Status and Possible Mechaisms. Int. J. Radiat. Oncol. Biol. Phys. 49, 379-389 (2001).
7. Heissig, B. et al. Low-dose Irradiation Promotes Tissue Revascularization Through VEGF Release from Mast Cells and MMP-9-mediated Progenitor Cell Mobilization. J. Exp. Med. 202, 739-750 (2005).
8. Datta, R. et al. Ionizing Radiation Activates Transcription of the EGR1 Gene Via CArG Elements. Proc. Natl. Acad. Sci. USA 89, 10149-10153 (1992).
9. Weichselbaum, R. R. et al. Gene Therapy Targeted by Radiation Preferentially Radiosensitizes Tumor Cells. Cancer Res. 54, 4266-4269 (1994).
10. Hallahan, D. E. et al. Spatial and Temporal Control of Gene Therapy Using Ionizing Radiation. Nat. Med. 1, 786-791 (1995).
11. Chung, T. D. et al. Tumor Necrosis Factor-alpha-based Gene Therapy Enhances Radiation Cytotoxicity in Human Prostate Cancer. Cancer Gene Ther. 5, 344-349 (1998).
12. Staba, M. J., Mauceri, H. J., Kufe, D. W., Hallahan, D. E., and Weichselbaum, R. R. Adenoviral TNF-alpha Gene Therapy and Radiation Damage Tumor Vasculature in a Human Malignant Glioma Xenograft. Gene Ther 5, 293-300 (1998).
13. Mundt, A. J. et al. A Phase I Trial of TNFerade Biologic in Patients With Soft Tissue Sarcoma in the Extremities. Clin. Cancer Res. 10, 5747-5753 (2004).
14. Barnett, B. G., Crews, C. J., and Douglas, J. T. Targeted Adenoviral Vectors. Biochim. Biophys. Acta. 1575, 1-14 (2002).
15. Curiel, D. T. Strategies to Adapt Adenoviral Vectors for Targeted Delivery. Ann. NY Acad. Sci. 886, 158-171 (1999).
16. Coins, W. F. et al. Delivery Using Herpes Simplex Virus: An Overview. Methods Mol. Biol. 246, 257-299 (2004).
17. Chen, X. et al. Novel Endothelial Cell Markers in Hepatocellular Car-cinoma. Mod. Pathol. 17, 1198-1210 (2004).
18. Hardwick, J. S. et al. Identification of Biomarkers for Tumor Endothelial Cell Proliferation Through Gene Expression Profiling. Mol. Cancer Ther. 4, 413-425 (2005).
19. Khodarev, N. N. et al. Tumour-endothelium Interactions in Coculture: Coordinated Changes of Gene Expression Profiles and Phenotypic Properties of Endothelial Cells. J. Cell Sci. 116, 1013-1022 (2003).
20. Kwon, Y., Han, Z., Karatan, E., Mrksich, M., and Kay, B. K. Antibody Arrays Prepared by Cutinase-mediated Immobilization on Self-assembled Monolayers. Anal. Chem. 76, 5713-5720 (2004).
21. Espina, V., Dettloff, K. A., Cowherd, S., Petricoin, E. F., III, and Liotta, L. A. Use of Proteomic Analysis to Monitor Responses to Biological Therapies. Expert Opin. Biol. Ther. 4, 83-93 (2004).
22. McDonald, W. H. and Yates, J. R., III. Shotgun Proteomics and Biomarker Discovery. Dis. Markers 18, 99-105 (2002).
23. Arap, W. et al. Steps Toward Mapping the Human Vasculature by Phage Display. Nat. Med. 8, 121-127 (2002).
24. Joyce, J. A. et al. Stage-specific Vascular Markers Revealed by Phage Display in a Mouse Model of Pancreatic Islet Tumorigenesis. Cancer Cell 4, 393-403 (2003).
25. Romanczuk, H. et al. Modification of an Adenoviral Vector with Bio-logically Selected Peptides: A Novel Strategy for Gene Delivery to Cells of Choice. Hum. Gene Ther. 10, 2615-2626 (1999).
26. Smith, G. P. Filamentous Fusion Phage: Novel Expression Vectors that Display Cloned Antigens on the Virion Surface. Science 228, 1315-1317 (1985).
27. Scott, J. K. and Smith, G. P. Searching for Peptide Ligands with an Epitope Library. Science 249, 386-390 (1990).
28. Parmley, S. F. and Smith, G. P. Filamentous Fusion Phage Cloning Vectors for the Study of Epitopes and Design of Vaccines. Adv. Exp. Med. Biol. 251, 215-218 (1989).
29. Cesareni, G., Castagnoli, L., and Cestra, G. Phage Displayed Peptide Libraries. Comb. Chem. High Throughput Screen 2, 1-17 (1999).
30. Sidhu, S. S. Phage Display in Pharmaceutical Biotechnology. Curr. Opin. Biotechnol. 11, 610-616 (2000).
31. Dani, M. Peptide Display Libraries: Design and Construction. J. Recept. Signal Transduct. Res 21, 469-488 (2001).
32. Pini, A., Giuliani, A., Ricci, C., Runci, Y., and Bracci, L. Strategies for the Construction and Use of Peptide and Antibody Libraries Displayed on Phages. Curr. Protein Pept. Sci. 5, 487-496 (2004).
33. Arap, W., Pasqualini, R., and Ruoslahti, E. Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model. Science 279, 377-380 (1998).
34. Pasqualini, R. and Ruoslahti, E. Organ Targeting In Vivo Using Phage Display Peptide Libraries. Nature 380, 364-366 (1996).
35. Ruoslahti, E. Vascular Zip Codes in Angiogenesis and Metastasis. Biochem. Soc. Trans. 32, 397-402 (2004).
36. Koivunen, E., Wang, B., and Ruoslahti, E. Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-directed Integrins. Biotechnology (NY) 13, 265-270 (1995).
37. Zitzmann, S., Ehemann, V., and Schwab, M. Arginine-glycine-aspartic Acid (RGD)-peptide Binds to Both Tumor and Tumor-endothelial Cells In Vivo. Cancer Res. 62, 5139-5143 (2002).
38. Pasqualini, R. et al. Aminopeptidase N is a Receptor for Tumor-homing Peptides and a Target for Inhibiting Angiogenesis. Cancer Res. 60, 722-777 (2000).
39. Kondo, M. et al. Anti-neovascular Therapy by Liposomal Drug Targeted to Membrane Type-1 Matrix Metalloproteinase. Int. J. Cancer 108, 301-306 (2004).
40. Ohkubo, S. et al. Identification of Substrate Sequences for Membrane Type-1 Matrix Metalloproteinase Using Bacteriophage Peptide Display Library. Biochem. Biophys. Res. Commun. 266, 308-313 (1999).
41. Laakkonen, P. et al. Antitumor Activity of a Homing Peptide That Targets Tumor Lymphatics and Tumor Cells. Proc. Natl. Acad. Sci. USA 707, 9381-9386 (2004).
42. Laakkonen, P., Porkka, K., Hoffman, J. A., and Ruoslahti, E. A Tumor-homing Peptide with a Targeting Specificity Related to Lymphatic Vessels. Nat. Med. 8, 751-755 (2002).
43. Asai, T. et al. Isolation of a Novel Peptide Homing to Tumor-derived Neovasculature That Suppresses Tumor Growth. Dial. Pharm. Bull. 25, 904-906 (2002).
44. Essler, M. and Ruoslahti, E. Molecular Specialization of Breast Vasculature: A Breast-homing Phage-displayed Peptide Binds to Aminopeptidase P in Breast Vasculature. Proc. Natl. Acad. Sci. USA 99, 2252-2257 (2002).
45. Porkka, K., Laakkonen, P., Hoffman, J. A., Bernasconi, M., and Ruoslahti, E. A Fragment of the HMGN2 Protein Homes to the Nuclei of Tumor Cells and Tumor Endothelial Cells In Vivo. Proc. Natl. Acad. Sci. USA 99, 7444-7449 (2002).
46. Christian, S. et al. Nucleolin Expressed at the Cell Surface is a Marker of Endothelial Cells in Angiogenic Blood Vessels. J. Cell. Biol. 765, 871-878 (2003).
47. Oku, N. et al. Anti-neovascular Therapy Using Novel Peptides Homing to Angiogenic Vessels. Oncogene 21, 2662-2669 (2002).
48. Asai, T. et al. Anti-neovascular Therapy by Liposomal DPP-CNDAC Targeted to Angiogenic Vessels. FEBS Lett 520, 167-170 (2002).
49. Arap, W. et al. Targeting the Prostate for Destruction Through a Vascular Address. Proc. Natl. Acad. Sci. USA 99, 1527-1531 (2002).
50. Zurita, A. J. et al. Combinatorial Screenings in Patients: The Interleukin-11 Receptor Alpha as a Candidate Target in the Progression of Human Prostate Cancer. Cancer Res. 64, 435-439 (2004).
51. Hoffman, J. A. et al. Progressive Vascular Changes in a Transgenic Mouse Model of Squamous Cell Carcinoma. Cancer Cell 4, 383-391 (2003).
52. Mintz, P. J. et al. Fingerprinting the Circulating Repertoire of Antibodies from Cancer Patients. Nat. Biolechnol. 21, 57-63 (2003).
53. Arap, M. A. et al. Cell Surface Expression of the Stress Response Chaperone GRP78 Enables Tumor Targeting by Circulating Ligands. Cancer Cell 6, 275-284 (2004).
54. Mutuberria, R. et al. Isolation of Human Antibodies to Tumor-associated Endothelial Cell Markers by In Vitro Human Endothelial Cell Selection with Phage Display Libraries. J. Immunol. Methods 287, 31-47 (2004).
55. Kennel, S. J., Lankford, T., Foote, L., Wall, M., and Davern, S. Phage Display Selection of scFv to Murine Endothelial Cell Membranes. Hybrid Hybridomics 23, 205-211 (2004).
56. Zitzmann, S. et al. Identification of a New Prostate-specific Cyclic Peptide with the Bacterial FliTrx System. J. Nucl. Med. 46, 782-785 (2005).
57. Hallahan, D. et al. Integrin-mediated Targeting of Drug Delivery to Irradiated Tumor Blood Vessels. Cancer Cell 3, 63-74 (2003).
58. Stefanidakis, M. and Koivunen, E. Peptide-mediated Delivery of Therapeutic and Imaging Agents into Mammalian Cells. Curr. Pharm. Des. 10, 3033-3044 (2004).
59. White, S. J. et al. Targeted Gene Delivery to Vascular Tissue In Vivo by Tropism-modified Adeno-associated Virus Vectors. Circulation 709, 513-519 (2004).
60. Grifman, M. et al. Incorporation of Tumor-targeting Peptides into Recombinant Adeno-associated Virus Capsids. Mol. Ther. 3, 964-975 (2001).
61. Muller, O. J. et al. Random Peptide Libraries Displayed on Adeno-associated Virus to Select for Targeted Gene Therapy Vectors. Nat. Biotechnol. 21, 1040-1046 (2003).
62. Zhang, L., Huffman, J. A., and Ruoslahti, E. Molecular Profiling of Heart Endothelial Cells. Circulation 112, 1601-1611 (2005).
63. Boulter, J. M. and Jakobsen, B. K. Stable, Soluble, High-affinity, Engineered T cell Receptors: Novel Antibody-like Proteins for Specific Targeting of Peptide Antigens. Clin. Exp. Immunol. 142, 454-460 (2005).
64. Holt, L. J., Herring, C., Jespers, L. S., Woolven, B. P., and Tomlinson, I. M. Domain Antibodies: Proteins for Therapy. Trends Biotechnol. 27, 484-490 (2003).
65. Schlehuber, S. and Skerra, A. Anticalins as an Alternative to Antibody Technology. Expert Opin. Biol. Ther. 5, 1453-1462 (2005).
66. Carlos, T. M. and Harlan, J. M. Leukocyte-endothelial Adhesion Molecules. Blood 84, 2068-2101 (1994).
67. Ebnet, K. and Vestweber, D. Molecular Mechanisms that Control Leukocyte Extravasation: The Selectins and The Chemokines. Histochem. Cell Biol. 112, 1-23 (1999).
68. Wu, N. Z. et al. Differences in Leucocyte-endothelium Interactions Between Normal and Adenocarcinoma Bearing Tissues in Response to Radiation. Br. J. Cancer 69, 883-889 (1994).
69. Kimura, H. et al. Inhibition of Radiation-induced Up-regulation of Leukocyte Adhesion to Endothelial Cells with the Platelet-activating Factor Inhibitor, BN52021. Int. J. Radiat. Oncol. Biol. Phys. 33, 627-633 (1995).
70. Molla, M. et al. Influence of Dose-rate on Inflammatory Damage and Adhesion Molecule Expression after Abdominal Radiation in the Rat. Int. J. Radiat. Oncol. Biol. Phys. 45, 1011-1018 (1999).
71. Yuan, H. et al. Radiation-induced Permeability and Leukocyte Adhesion in the Rat Blood-brain Barrier: Modulation with Anti-ICAM-1 Antibodies. Brain Res. 969, 59-69 (2003).
72. Hallahan, D. E. et al. Targeting Drug Delivery to Radiation-induced Neoantigens in Tumor Microvasculature. J. Control Release 74, 183-191 (2001).
73. Wickham, T. J., Carrion, M. E., and Kovesdi, I. Targeting of Adenovirus Penton Base to New Receptors Through Replacement of its RGD Motif with Other Receptor-specific Peptide Motifs. Gene Ther. 2, 750-756 (1995).
74. Hallahan, D. E., Staba-Hogan, M. J., Virudachalam, S., and Kolchinsky, A. X-ray-induced P-selectin Localization to the Lumen of Tumor Blood Vessels. Cancer Res. 58, 5216-5220 (1998).
75. Kobayashi, T. et al. The Tetraspanin CD63/lamp3 Cycles Between Endocytic and Secretory Compartments in Human Endothelial Cells. Mol. Biol. Cell 11, 1829-1843 (2000).
76. Friedman, M. et al. Reversible Alterations in Cultured Pulmonary Artery Endothelial Cell Monolayer Morphology and Albumin Permeability Induced by Ionizing Radiation. J. Cell Physiol. 129, 237-249 (1986).
77. Shin, B. K. et al. Global Profiling of the Cell Surface Proteome of Cancer Cells Uncovers an Abundance of Proteins with Chaperone Function. J. Biol. Chem. 278, 7607-7616 (2003).
78. Rybak, J. N. et al. In Vivo Protein Biotinylation for Identification of Organ-specific Antigens Accessible from the Vasculature. Nat. Methods 2, 291-298 (2005).
79. Peirce, M. J., Wait, R., Begum, S., Saklatvala, J., and Cope, A. P. Ex-pression Profiling of Lymphocyte Plasma Membrane Proteins. Mol. Cell Proteomics 3, 56-65 (2004).
80. Sharma, B., et al. Antisense Targeting of Perlecan Blocks Tumor Growth and Angiogenesis In Vivo. J. Clin. Invest. 102, 1599-1608 (1998).
81. Babic, A. M., Kireeva, M. L., Kolesnikova, T. V., and Lau, L. F. CYR61, A Product of a Growth Factor-inducible Immediate Early Gene, Promotes Angiogenesis and Tumor Growth. Proc. Natl. Acad. Sci. USA 95, 6355-6360 (1998).
82. Kayed, H. et al. Localization of the Human Hedgehog-interacting Protein (Hip) in the Normal and Diseased Pancreas. Mol. Carcinog. 42, 183-92 (2005).
83. Bischoff, J. R. et al. An Adenovirus Mutant that Replicates Selectively in p53-deficient Human Tumor Cells. Science 274, 373-376 (1996).
84. Nemunaitis, J. et al. Phase II Trial of Intratumoral Administration of ONYX-015, A Replication-selective Adenovirus, in Patients with Refractory Head and Neck Cancer. J. Clin. Oncol. 19, 289-298 (2001).
85. Chiocca, E. A. Oncolytic Viruses. Nat. Rev. Cancer 2, 938-950 (2002).
86. Nemunaitis, J. and Edelman, J. Selectively Replicating Viral Vectors. Cancer Gene Ther. 9, 987-1000 (2002).
87. Rodriguez, R. et al. Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells. Cancer Res. 57, 2559-2563 (1997).
88. Puhlmann, M. et al. Vaccinia as a Vector for Tumor-directed Gene Therapy: Biodistribution of a Thymidine Kinase-deleted Mutant. Cancer Gene Ther. 7, 66-73 (2000).
89. McCart, J. A. et al. Systemic Cancer Therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes. Cancer Res. 61, 8751-8757 (2001).
90. Stanziale, S. F. et al. Ionizing Radiation Potentiates the Antitumor Efficacy of Oncolytic Herpes Simplex Virus G207 by Upregulating Ribonucleotide Reductase. Surgery 132, 353-359 (2002).
91. Kim, S. H. et al. Combination of Mutated Herpes Simplex Virus Type 1 (G207 Virus) With Radiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck. Eur. J. Cancer 41, 313-322 (2005).
92. Mezhir, J. J. et al. Ionizing Radiation Activates Late Herpes Simplex Virus 1 Promoters Via the p38 Pathway in Tumors Treated with Oncolytic Viruses. Cancer Res. 65, 9479-9484 (2005).
93. Qian, J. et al. Ionizing Radiation-induced Adenovirus Infection is Mediated by Dynamin 2. Cancer Res. 65, 5493-5497 (2005).